What one share of In8bio holds
We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers ("TCEs") for cancer and autoimmune diseases.
In8bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.48 |
|---|---|
| Cash and investments | $1.84 |
| Book value | $1.86 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$90.73 | — | — | — | −$132.12 |
| 2021 | — | −$44.09 | — | — | — | −$60.99 |
| 2022 | — | −$40.81 | — | — | — | $27.78 |
| 2023 | — | −$30.14 | — | — | — | $17.28 |
| 2024 | — | −$17.05 | — | — | — | $5.99 |
| 2025 | — | −$4.44 | — | — | — | $2.82 |
Common questions about In8bio
How much does one share of In8bio earn?
Over the last 12 months, In8bio lost $1.48 for each share.
Does In8bio pay a dividend?
In8bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is In8bio’s book value per share?
In8bio’s book value is $1.86 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of In8bio have?
Each share of In8bio has $1.84 of cash and investments, as of June 30, 2026.
Has In8bio bought back shares?
In8bio’s share count rose about 3738% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.